1-11 of 11
Ante S. Lundberg
Close
Sort by
Journal Articles

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus

Chiara Antoniani, Vasco Meneghini, Annalisa Lattanzi, Tristan Felix, Oriana Romano, Elisa Magrin, Leslie Weber, Giulia Pavani, Sara El Hoss, Ryo Kurita, Yukio Nakamura, Thomas J. Cradick, Ante S. Lundberg, Matthew Porteus, Mario Amendola, Wassim El Nemer, Marina Cavazzana, Fulvio Mavilio, Annarita Miccio
Journal: Blood
Blood (2018) 131 (17): 1960–1973.
https://doi.org/10.1182/blood-2017-10-811505
Published: 2018
Includes: Supplemental data
Journal Articles

Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia

Michelle I Lin, PhD, Elizabeth J Paik, PhD, Bibhu P Mishra, PhD, Song Chou, PhD, Ying Zhang, PhD, Kaleigh Tomkinson, MS, Michael A Pettiglio, BS, Andrew Sanginario, BS, Amanda Woo, BS, Min Jin Lee, BS, Melanie Allen, MS, Thomas J Cradick, PhD, Tirtha Chakraborty, PhD, Matthew Porteus, MD PhD, Ciaran M Lee, PhD, Gang Bao, PhD, Annarita Miccio, PhD, Annalisa Lattanzi, PhD, Fulvio Mavilio, PhD, Chad A Cowan, PhD, Rodger Novak, MD, Ante S Lundberg, MD
Journal: Blood
Blood (2016) 128 (22): 4708.
https://doi.org/10.1182/blood.V128.22.4708.4708
Published: 2016
Journal Articles

Induction of Fetal Hemoglobin Synthesis By Crispr/Cas9-Mediated Disruption of the β-Globin Locus Architecture

Chiara Antoniani, MSc, Vasco Meneghini, Annalisa Lattanzi, PhD, Giulia Pavani, PhD, Tristan Felix, MSc, Fatima Amor, MSc, Oriana Romano, Elisa Magrin, PhD, Leslie Weber, MSc, Thomas Cradick, Ante S Lundberg, MD, Matthew Porteus, MD PhD, Mario Amendola, Marina Cavazzana, MD PhD, Fulvio Mavilio, PhD, Annarita Miccio, PhD
Journal: Blood
Blood (2016) 128 (22): 321.
https://doi.org/10.1182/blood.V128.22.321.321
Published: 2016
Journal Articles

Crispr/Cas9- Mediated Genome Editing of Human CD34 + Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies

Bibhu Mishra, PhD, Song Chou, PhD, Michelle I Lin, PhD, Elizabeth J Paik, PhD, Ying Zhang, PhD, Ruibin Liang, MS, Kaleigh Tomkinson, MS, Michael Pettiglio, MS, Andrew Sanginario, BS, Melanie Allen, MS, Thomas Cradick, PhD, Matthias John, PhD, Tirtha Chakraborty, PhD, Chad A Cowan, PhD, Rodger Novak, MD, Ante S Lundberg, MD
Journal: Blood
Blood (2016) 128 (22): 3623.
https://doi.org/10.1182/blood.V128.22.3623.3623
Published: 2016
Journal Articles

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Antonio M Risitano, MD PhD, Michael Storek, Leonardo Sahelijo, MD, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, MD, Judith C.W. Marsh, MD, Modupe Elebute, MBChB, MD, Casey L O'Connell, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Giridharan Ramsingh, MD, Serena Marotta, MD, Andrzej Hellmann, Ante S. Lundberg, MD
Journal: Blood
Blood (2015) 126 (23): 2137.
https://doi.org/10.1182/blood.V126.23.2137.2137
Published: 2015
Journal Articles

Complement Activation in Patients with Acquired Thrombotic Thrombocytopenic Pupura (TTP)

Shangbin Yang, Spero R Cataland, M.D., V. Michael Holers, M.D., Ante S Lundberg, M.D., Haifeng Wu, M.D.
Journal: Blood
Blood (2012) 120 (21): 3323.
https://doi.org/10.1182/blood.V120.21.3323.3323
Published: 2012
Journal Articles

Mortality From Thrombotic Thrombocytopenic Purpura Is Related to Complement Hyperactivation

Trudy C. Wu, Shangbin Yang, Sara Haven, V. Michael Holers, M.D., Ante S. Lundberg, M.D., Haifeng Wu, M.D., Spero R. Cataland, M.D.
Journal: Blood
Blood (2012) 120 (21): 488.
https://doi.org/10.1182/blood.V120.21.488.488
Published: 2012
Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers
Journal: Blood
Blood (2011) 118 (17): 4705–4713.
https://doi.org/10.1182/blood-2011-06-359646
Published: 2011
Includes: Supplemental data
Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD
Journal: Blood
Blood (2010) 116 (21): 638.
https://doi.org/10.1182/blood.V116.21.638.638
Published: 2010
Journal Articles

Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.

Harry P Erba, Margaret O'Donnell, Steven L Allen, Maria R Baer, Bayard L Powell, Richard M Stone, John M Bennett, Ante S Lundberg, Robert L Capizzi, David A Rizzieri
Journal: Blood
Blood (2009) 114 (22): 1047.
https://doi.org/10.1182/blood.V114.22.1047.1047
Published: 2009
Journal Articles

Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML

Steven L Allen, Harry P Erba, David A. Rizzieri, Margaret O’Donnell, Bayard Powell, Ante S Lundberg, John M Bennett, Robert L Capizzi
Journal: Blood
Blood (2008) 112 (11): 2968.
https://doi.org/10.1182/blood.V112.11.2968.2968
Published: 2008